Diabetes medication class tied to lower risk

<p>Type 2 diabetes is associated with increased risk of kidney stones, but some forms of treatment for this condition may also have the benefit of lowering risk of kidney stones. In a study led by investigators from <a href="https://www.massgeneralbrigham.org/" target="_blank">Mass General Brigham</a>, researchers found that there was an association between the use of sodium-glucose contratransporter 2 (SGLT2) inhibitors and a lower risk of developing kidney stones. Their findings are reported in <a href="https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2814491?utm_campaign=articlePDF&amp;utm_medium=articlePDFlink&amp;utm_source=articlePDF&amp;utm_content=jamainternmed.2023.7660" target="_blank">JAMA Internal Medicine</a>.&nbsp;</p>

Related Keywords

United States ,Massachusetts ,Garyc Curhan ,Julie Paik ,Helen Tesfaye ,Deborahj Wexler ,Heidi Zakoul ,Method Of Research ,Drug Administration ,Outcomes Research Institute ,Division Of Renal Kidney Medicine At Brigham ,National Institute Of Aging ,Glaxosmithkline ,Boehringer Ingelheim ,Department Of Medicine ,Division Of Pharmacoepidemiology ,National Institute Of Arthritis ,Harvard Medical School ,Novo Nordisk ,Mass General Brigham ,Massachusetts General Hospital ,Additional Mass General Brigham ,Elisabetta Patorno ,National Institute ,Patient Centered Outcomes Research Institute ,Skin Diseases ,Glucose Cotransporter ,Nephrolithiasis Risk ,Patients With Type ,General Brigham ,